ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?

In a fresh comparison of two specialty‑focused pharmaceutical players, ANI Pharmaceuticals (ANIP) and Amneal Pharmaceuticals (AMRX) go head‑to‑head — and ANIP currently has the upper hand. According to the analysts at Zacks Investment Research, ANIP’s rare-disease and generics business has delivered strong growth in 2025, largely thanks to robust demand for its ACTH‑based injection Cortrophin Gel. In the first nine months of the year, revenue from rare diseases more than doubled, with Cortrophin Gel alone contributing $236 million — a 70% increase year-over-year. For the full year, ANIP expects Cortrophin Gel sales of $347–$352 million, reflecting a 75–78% increase compared with 2024. Meanwhile, ANIP’s generics side still provides stability, including support from new product launches. However, generics revenue growth may slow down in Q4 as more competitors enter the market. On the rare‑disease front, ANIP faces intensifying competition — chiefly from Keenova Therapeutics (formerly Mallinckrodt), which markets competing ACTH‑based therapies. Despite that, ANIP appears well‑positioned to maintain momentum. On the other side, AMRX offers a more diversified structure: its business spans “Affordable Medicines” (generics, injectables, biosimilars, international sales), a Specialty segment (CNS, endocrine therapies), and a government‑distribution arm called AvKARE. For 2025, the company projects revenue between $3.0 and $3.1 billion — up 7.5–11% year-over-year. While its generics scale and manufacturing footprint remain competitive, AMRX is under pressure from shrinking generic drug prices, increased biosimilar competition, and recent loss of exclusivity on some specialty drugs (e.g., the CNS therapy previously sold under the brand “Rytarvy”). The AvKARE segment also carries some volatility tied to government procurement cycles. Comparing forecasts: ANIP’s 2025 sales are expected to grow ~42% year-over-year, with earnings per share (EPS) rising roughly 45%. In contrast, AMRX expects about 8% sales growth in 2025, though EPS is projected to jump over 36%. In terms of valuation, ANIP trades at a forward P/E of ~12.7× — cheaper than AMRX’s ~14.8×. Additionally, Zacks assigns ANIP a “Rank #1 (Strong Buy)” rating, compared with a “Rank #3 (Hold)” for AMRX. All told, while both companies remain financially solid and diversified, ANIP’s rare‑disease success and lower valuation give it an edge — making it the more compelling pick for investors eyeing growth in the niche drug marketplace. #PharmaStocks #Drugmakers #ANIP #AMRX #SlimScan #GrowthStocks #CANSLIM